Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($2.79), may not compare to the analyst estimate of ($0.22). Revenue for the quarter came in at $466.3 million versus the consensus estimate of $446.22 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.